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Background: Globally, 14.3% of women of reproductive age use intrauterine contraception (IUC), but the distribution of IUC users is
strikingly nonuniform. In some countries, the percentage of women using IUC is b2%, whereas in other countries, it is N40%. Reasons for
this large variation are not well documented. The aims of this review are to describe the worldwide variation in IUC utilization and to explore
factors that impact utilization rates among women of reproductive age in different continents and countries.
Study Design: Published literature from 1982 to 2012 was reviewed, using Medline and Embase, to identify publications reporting
diverse practices of IUC provision, including variation in the types of IUC available. Local experts who are active members of international
advisory groups or congresses were also consulted to document variations in practice regulations, published guidelines and cost of IUC in
different countries.
Results: Multiple factors appear to contribute to global variability in IUC use, including government policy on family planning, the types of
health care providers (HCPs) who are authorized to place and remove IUC, the medicolegal environment, the availability of practical training
for HCPs, cost differences and the geographical spread of clinics providing IUC services.
Conclusions: Our review shows that the use of IUC is influenced more by factors such as geographic differences, government policy and the
HCP's educational level than by medical eligibility criteria. These factors can be influenced through education of HCPs and greater
understanding among policy makers of the effectiveness and cost-effectiveness of IUC methods.
Implications: Globally, 14.3% of women of reproductive age use IUC, but the percentage of women using IUC is in some countries b2%,
whereas in other countries, it is N40%. This paper reviews the reasons for this diverse and highlights possible starting points to improve the
inclusion of IUC in contraceptive counseling.
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Globally, 14.3% of women aged 15–49 years who are
married or in union use intrauterine contraception (IUC) [1].
However, among women who use contraception, the
percentage that use IUC varies greatly between continents/
regions; from 1.8% in Oceania to 27.0% in Asia (Fig. 1) [1].
The distribution of IUC users is also geographically skewed:
more than 80% of the world's IUC users live in Asia, with
almost two-thirds (64%) of them living in China (Fig. 2) [1].
International experts in contraception have been suggest-
ing that increasing the very low update rate of long-acting
reversible contraception (LARC) may reduce the rate of
unintended pregnancy [2]. This fact is also supported by an BY-NC-ND license.
Fig. 1. Percentage of contraceptors (the subset of women who are using any form of contraception) aged 15–49 years, married or in union, who use IUC [1].
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reversible contraceptives with other commonly prescribed
contraceptive methods. The authors could show that the
LARCs were superior to the other methods [3]. Although the
evidence would suggest that these methods can be offered to
most women of reproductive age, regardless of parity, in
some countries only a small percentage of contraceptive
users take up this method [4]. In this article, we aimed to
explore the worldwide diversity of practice with regard to
IUC, and the underlying factors that might explain the
differences were noted. We aimed to use both the published
literature and sought first-hand experience about local
practices from experts across the globe.Fig. 2. Worldwide distribution of IUC users. Eighty-three percent of the
world's IUC users are in Asia. The remaining 8%, 4%, 4%, 1% and 0.03%
are in Europe, Latin America/Caribbean, Africa, North America and
Oceania, respectively. Data have been calculated from United Nations 2011
data tables based on data from surveys of women aged 15–49 years who are
married or in union [1].2. Methods
We undertook a review of published literature using
EMBASE, PubMed and Medline between 1982 and 2012 to
explore IUC practices in various countries using the search
terms “intrauterine contraception,” “IUD” “practices,” and
“training.” We also drew on a pool of experts from across
the globe to explore disparities that existed but that were not
necessarily documented in published studies, especially
variations in national guidelines, differences in placement
recommendations and nation-specific differences in the
costs of various types of IUC and the reimbursement
systems in place. We consulted with clinicians in different
countries and cross-checked information about prices and
country-specific guidance from a number of sources
including key professional organizations and national
pharmaceutical databases.3. Results
3.1. Geographical variability in the prevalence of IUC use
Only 62.7% of women worldwide use any form of
contraception, although the use of contraception is more
prevalent in more developed areas (72.4% of women) than in
less developed areas (61.2% of women) (Table 1) [1].
Globally, 14.3% of women and 22.8% of women using
contraception use IUC (Table 1; Fig. 1). However, the use of
IUC is more prevalent in the less developed areas of the
world (15.1% of women; 24.7% of contraception users) than
in the more developed areas (9.2% of women; 12.7% of
contraception users) (Fig. 1; Table 1) [1].
3.1.1. Variation between continents
The highest rate of IUC use is in Asia (17.9% and 27.0%
of women and contraception users, respectively), followed
by Europe (12.4%; 17.1%), Africa (4.4%; 15.4%), Latin
America/Caribbean (7.0%; 9.6%), North America (4.8%;
6.1%) and Oceania (1.1%; 1.8%) (Table 1; Fig. 1) [1].
Table 1
United Nations data on worldwide contraceptive use, 2011 [1]
Geographical area Women aged 15–49 y married or in union (%)
Using any
method of
contraception
Using any
modern method
of contraception
Using
IUC
methods
Worldwide 62.7 56.1 14.3
More developed areas 72.4 61.3 9.2
Less developed areas 61.2 55.2 15.1
Africa (overall) 28.6 22.4 4.4
Sub-Saharan Africa 21.8 15.7 0.5
Northern Africa,
excluding Sudan
60.5 54.0 22.3
Eastern Africa 28.4 22.9 0.5
Middle Africa 18.6 6.6 0.2
Northern Africa 50.4 44.8 18.1
Southern Africa 58.4 58.1 1.1
Western Africa 14.4 8.7 0.7
Asia (overall) 66.2 60.2 17.9
Central Asia 56.8 51.5 41.5
Eastern Asia 82.8 81.3 37.8
Southern Asia 53.9 45.8 2.0
South-Eastern Asia 62.2 54.7 9.9
Western Asia 55.1 35.8 14.2
Europe (overall) 72.6 58.7 12.4
Eastern Europe 74.9 54.3 16.3
Northern Europe 80.1 77.2 11.9
Southern Europe 63.8 46.3 5.7
Western Europe 71.9 68.6 11.4
Latin America and
Caribbean (overall)
72.9 67.0 7.0
Caribbean 61.6 57.0 11.3
Central America 68.2 63.0 9.6
South America 76.1 69.6 5.5
North America (overall) 78.1 72.9 4.8
Canada 74.0 72.0 1.0
United States 78.6 73.0 5.3
Oceania (overall) 59.8 56.7 1.1
Australia/New Zealand 71.6 71.1 1.3
Melanesia/Micronesia/
Polynesia
36.7 28.6 0.7
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In addition to the variation in IUC use that exists between
continents, wide variations exist within some continents.
3.1.2.1. Asia. Within Asia, there is an extremely wide
regional variation in the proportion of women using IUC
(Table 1) [1]. Looking at individual Asian countries, in
China, the Democratic Peoples' Republic of Korea and
Vietnam, 41%–44% of women use IUC, compared with
some other countries in the region that have IUC
utilization rates of less than 2% [1]. In addition, data
from Chinese national surveys conducted by the National
Population and Family Planning Committee have shown
that in married women aged 15–49 years, there has been
an increase in IUC use from 42.1% in 1988 to 48.0% in
2006 [5].
3.1.2.2. Europe. The proportion of women using IUC in
Europe also shows tremendous variation by region (Table 1)and country. The highest rates of IUC use are in Estonia
(35.9% of women), and the rates range between 16% and
28% in countries such as France, Slovenia, Latvia and the
Scandinavian countries. In contrast, less than 8% of women
use IUC in Ireland, Germany and Romania [1]. In addition,
in a survey of randomly selected women aged 18–49 years
from five European countries (approximately 200 women
per country), the reported prevalence of IUC use was 19.0%
in Sweden, 13.4% in France, 10.3% in the UK, 5.0% in
Germany and 3.5% in Romania [6].
3.1.2.3. Africa. There is a clear dichotomization within
Africa regarding IUC use: the proportions of women using
IUC are very low (b2%) in the sub-Saharan, Eastern,
Middle, Southern and Western regions, whereas they are
high in Northern Africa (18.1% of women, or 22.3% if
Sudan is excluded) (Table 1), with “hot spots” for IUC use in
Tunisia and Egypt (27.8% and 36.1% of women, respec-
tively) [1].
3.1.2.4. North America. The use of IUC has increased over
recent years in North America, with ~5% of women (5.3% in
the US, 1.0% in Canada) now using these methods [1]. Data
from the 2006−2010 National Survey of Family Growth
show that, among contraceptors (rather than all women) aged
15–44 years, 7.7% used IUC [7]. In addition, rates of IUC
use in the US are influenced by ethnicity. For example,
Hispanic women are more likely to use IUC than Caucasian
women [8].
3.1.2.5. Other. The percentages of women in Latin
America who use IUC vary regionally (9.6% in Central
America; 5.5% in South America). In the Caribbean, 11.3%
of women use IUC. By contrast, less than 2% of women in
Oceania use IUC methods (Table 1) [1].
3.2. Types of IUC used in different countries: disparity in
the variety of devices available and their costs to women
Although the use of IUC has been documented in almost
all countries around the world [1], a comprehensive
summary of the types of intrauterine devices (IUDs) used
in each country is not available. In the 1960s and 1970s,
inert IUDs were widely available, but issues concerning
infection with the Dalkon Shield caused it to be removed
from the market in 1975. Since then, most other inert
devices have gradually been replaced by other types of
devices, typically those containing copper [9,10]. Most
countries have at least one T-framed copper device, but
some countries produce and/or dispense up to 15 different
varieties of copper IUD; some of these are available only in
the country in which they are manufactured, whereas others
are exported, imported or reimported and renamed
(Table 2). In addition to copper IUC, hormonal IUC has
been introduced. The levonorgestrel-intrauterine system
(LNG-IUS), Mirena®, was first marketed in Finland in 1990
and is now available in over 120 countries throughout the
Table 2
Devices and costs worldwide
Country Devices available for use Cost of the device Cost of the placement procedure Who pays?/Reimbursem t
Europe
France Mirena® 125.37 EUR 38.40 EUR • Placement is reimburs up to 65% by public insurance and 35% by private
insurance; approximately 90% of the French population receives complementary
private insurance
Gynelle 375 30.50 EUR 38.40 EUR • Placement is reimburs up to 65% by public insurance and 35% by private
insurance; approximately 90% of the French population receives complementary
private insurance
• For women b18 years f age, IUD cost and the placement procedure can be
free in family planning c nics
Mona Lisa Cu375
Mona Lisa Cu 375 SL
Mona Lisa CuT
380A QL
Mona Lisa NT Cu380
Multiload Cu375
Multiload 375 SL
NT 380 standard
NT 380 short
TT380
UT 380 standard
UT 380 short
Germany Mirena® 195 EUR 155–255 EUR • Fully reimbursed by p lic and private insurances for treatment of heavy
menstrual bleeding and r contraception in women with certain illnesses that
contraindicate use of pil
• Partially or fully reimb rsed by public insurance for contraception in women
b20 y of age (the percen ge reimbursement depends on the woman's age)
• Contraception is never overed by private insurance
Flexi-T300 15–30 EUR (GyneFix® 120 EUR) 155–210 EUR • Fully reimbursed by p lic insurance for women b20 y of age
Flexi-T + 380
Multiload Cu375
• No reimbursement by ublic or private insurers for women ≥20 y of age
Multi-safe 375 short stem
T-safe 380A
GyneFix®
The Netherlands Mirena® ~150 EUR GP: 60 EUR • The consultation/place ent is totally reimbursed by the woman's health care
insurance if she has an u graded insurance, which is common in the Netherlands.Gynecologist: 95 EUR
Flexi-T 300 32–69 EUR GP 60 EUR
Flexi-T plus 300 Gynecologist: 95 EUR • Hospital costs vary fro hospital to hospital in the Netherlands according to
the agreement with the i urance companies, but are between 155 and 330 EUR,
so placement in total cos between 250 and 425 EUR including the device itself.
T-Safe Cu
Multiload Cu375
GyneFix® 108 EUR GP 60 EUR
Gynecologist:95 EUR
(continued on next page)
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Table 2 (continued)
Country Devices available for use Cost of the device Cost of the placement procedure Who pays?/Reimbursement
Sweden Mirena® 1000 SEK (119 EUR) Placement service is free of charge to
women when used for contraception
(however, women pay for the device
itself)
• Mirena® is subsidized in some regions for younger women (the threshold for
“younger” may be 20, 23 or 25 y depending on the region). For example, in
Stockholm, women b23 y of age pay 6 EUR for Mirena®
• Mirena® placement is free of charge to women when it is for contraceptive
purposes (the government reimburses the provider). However, women pay
20–30 EUR when Mirena® is placed for therapeutic (noncontraceptive) purposes
Nova T (380) 100–200 SEK (12–24 EUR) Placement service is free of charge • Provided free of charge to women in most (but not all) regions of Sweden
(providers are reimbursed by the regional health services)Flexi-T 300
Flexi-T plus 300 • In regions where devices are not provided free of charge, women pay between
100 and 200 SEK (12–24 EUR)
• Placement is performed free of charge to women (providers are reimbursed by
the government)
UK Mirena® Provided to women free of charge
by the National Health Service
Placement is free of charge to women
on the National Health Service
• Mirena® and copper IUD are provided and placed free of charge to women
(the provider is reimbursed by the National Health Service)
Cu-safe T300 Provided to women free of charge
by the National Health Service
Placement is free of charge to women
on the National Health ServiceFlexi-T300
• Private cost of copper devices: 8.52−26.64 GBP (9.97−31.37 EUR)
• Private cost of Mirena®: 88 GBP (103 EUR)
Flexi-T + 380 • Private placement fee for copper devices or Mirena®: 150−500 GBP
(176−585 EUR)Load 375
Mini TT 380
Multiload Cu375
Multi-safe 375
Multi-safe 375 short stem
Neo-safe T30
Nova-T 380
T-safe 380A
TT380 slimline
UT380 short
UT380 standard
GyneFix® Provided to women free of charge
by National Health Service
North America
USA Mirena® Up to 875 USD (up to 673 EUR) Up to 300 USD(up to 231 EUR) • Depending on a woman's insurance, she may pay nothing or up to 875 USD
for Mirena® or ParaGard®ParaGard® Up to 875 USD (up to 673 EUR) Up to 300 USD (up to 231 EUR)
• Some insurance plans cover the cost (or a proportion of the cost) of both the
device and its placement. Other plans may cover only the device or only the
placement and vice versa.
• Government-funded insurances vary considerably depending on the state the
woman lives in
• The new affordable care act in the US aims to provide contraception to all
women at no cost to themselves; however, it is not yet clear who will
cover these costs.
Canada Mirena® Up to 500 CAD(up to 378 EUR) Placement service is free of charge • Some publicly funded clinics will provide IUC at no cost to the woman.
• Some public and private insurance plans will cover IUC.Copper IUDs Up to 150 CAD (up to 113 EUR) Placement service is free of charge
• Insurance-plan coverage varies between provinces but usually covers
80%–100% of women.
• If women are not covered by insurance, IUC will be entirely their expense.
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Latin America
Argentina Mirena® 220 USD (169 EUR) 400–1000 USD (308–770 EUR) • Placement is available in private offices only.
• Women pay for Mirena® and its placement themselves.
Copper T380 10 USD (domestic manufacturing)
(8 EUR)
Private office: 150–300 USD
(115–231 EUR)
Insurance plan:60–90 USD (46–69 EUR)
• Women pay either the entire cost of the device and placement themselves
(if they do not have insurance that covers this form of contraception) or the cost
is partially reimbursed by the insurance company.
Copper T375
• In publicly funded clinics the cost of copper IUDs and their placement is free
to women
Brazil Mirena® 300 USD (231 EUR) Private office: 500 USD (385 EUR) • Women pay either the entire cost of Mirena® and its placement themselves
(if they do not have insurance that covers Mirena®) or the cost is partially
reimbursed by the insurance company.
Insurance plan: 50 USD (38 EUR)
• Insurance covers Mirena® for contraception and treatment of heavy
menstrual bleeding.
Copper T380 20 USD (15 EUR) Private office: 500 USD (385 EUR) • Women pay either the entire cost of the device and its placement themselves
(if they do not have insurance that covers this form of contraception) or the cost
is partially reimbursed by the insurance company.
Copper T375 Insurance plan: 50 USD (38 EUR)
Colombia Mirena® 240–350 USD (185–269 EUR) Private office: 190 USD (146 EUR)
(Mirena is not provided by publicly
funded clinics.)
• Women pay for Mirena® and its placement themselves
• Insurance covers Mirena® strictly for treatment of heavy menstrual bleeding,
not for contraception.
Copper T380 3–10 USD (2–8 EUR) Private office: 100 USD (77 EUR)
(cost of placement and device)
• Women in private office must pay for the device and its placement.
• Copper IUDs and their placement are fully reimbursed by some insurances.
• Women without insurance that covers copper IUDs pay the full cost of the
device and its placement themselves.
• In public clinics and hospitals, cost is covered by the government, so it is free
for women.
Insurance plan: 20–80 USD (15–62 EUR)
Mexico Mirena® 150 USD (115 EUR) Private office: 150 USD (115 EUR) • In private office, women must pay for Mirena® and for placement.
• Insurance companies do not cover the cost for contraception or treatment of
heavy menstrual bleeding.
• In some publicly
funded clinics, Mirena® is provided to women free of charge (the cost is
reimbursed by the government).
Copper T380 7 USD (5 EUR) Private office: 150 USD (115 EUR) • In private office, women must pay for copper IUDs and for placement.
Copper T375 Insurance plan: placement is not covered • Insurance companies do not cover the cost of copper IUDs.
• Women are provided with copper IUDs free of charge in public clinics
(providers are reimbursed by the government).
Public clinic: free of charge to women
Asia-Pacific
China Stainless steel rings Free of charge to women Free of charge to women • All copper and stainless steel IUDs are provided free of charge to women
(providers are reimbursed by the government).Copper devices
Australia Mirena® Public script: up to 35.40 AUD
(28.55 EUR)
0–200+ AUD(0–161+ EUR) • Mirena® is subsidized, i.e., the women and the government share the cost.
• Some hospital and sexual health clinics do not charge for fitting or only
charge Medicare rebate, and others charge a flat fee of 100–175 AUD
(81–141 EUR). Other practices may charge beyond this. This is the placement
fee only, not the consultation fee.
• Insurance plans cover the cost of the placement procedure, but not the cost of
the device.
Purchased online/private script:
250–400+ AUD (202–323+ EUR)
(continued on next page)
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168 K.J. Buhling et al. / Contraception 89 (2014) 162–173world, although in many countries, access is limited by the
cost [11,12].
Differences in the range of IUC options available may
affect access for numerous reasons. However, the most
obvious factor that influences access is cost [13,14].
Depending on the country, the cost of IUC and its
placement might be charged to the health care system,
insurance companies, nonprofit organizations or to women
themselves. Medical insurance plans vary in the types of
device covered and whether or not the cost of placement is
included. Furthermore, in low-resource settings, where
foreign aid is received for family planning, the methods of
contraception provided may reflect donor preferences or may
limit the contraceptive options available [15]. Obtaining
information on both the cost of manufacturing and the costs
to consumers is difficult, but costs are clearly not uniform
around the world. In the UK, T-framed, U-framed and
frameless copper devices and the LNG-IUS are available to
women free of charge through the National Health Service;
however, there is, of course, a cost to the health care system
(Table 2).
In the US, the available IUC options include one 10-year
T-shaped copper device (ParaGard®) and two LNG-IUSs
(Mirena® and Skyla®). Depending on a woman's insurance
plan, she could pay nothing or up to $875 for any of the
devices and up to $300 for the placement of the device.
Currently, women who have government-funded insurance
in the US have variable access to IUC depending on the state
in which they live. In 2014, the Patient Protection and
Affordable Care Act in the US (commonly known as
“ObamaCare”) will come into effect. Although it is unclear
how this act will impact the cost of IUC, the intention is for
all women to have access to contraception at no cost to
women themselves. However, there is considerable debate
over who would be responsible for covering this financial
burden and not all contraceptive methods have to be covered
in any given State's plan.
In China, stainless steel rings (Fig. 3) continue to be
placed despite the government's commitment to discontinue
this option and switch to the use of more effective devices
containing copper (Fig. 3) [16,17]. Whatever device a region
chooses is provided free of charge to the women there.
However, because stainless steel rings are less expensive for
the family planning clinics to buy, for many years, these
rings were the devices that were provided, despite their
higher expulsion and failure rates [16].
In some countries, one IUC device may be provided or
subsidized, whereas other devices are not. In Mexico and
in most parts of Sweden, copper IUDs are provided to
women free of charge, whereas women must pay for the
LNG-IUS themselves if it is the method they desire. In
New Zealand, the copper IUD is subsidized and is used
more widely than the LNG-IUS [18]. Conversely, the
LNG-IUS is subsidized in Australia under the Pharma-
ceutical Benefits scheme [19], and greater utilization is
noted compared with copper IUDs [20].
Fig. 3. IUDs (including those available only in China) [48].
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3.3.1. Types of health care providers authorized to provide
IUC services
Through practitioners working in different countries, we
obtained information about both the types of health care
providers (HCPs) that provide IUC and the settings in which
this provision occurs. One of the key variations is whether
countries train and permit placement by nurses and/ormidwives (Table 3). In Germany, IUC services are provided
only by obstetrician-gynecologists. In the neighboring
Netherlands, IUC services are provided by a wider range
of HCPs, including family practice physicians and general
practitioners. In Sweden, midwives provide most contracep-
tive services.
Differences in the types of HCP that are authorized to
provide IUC services have a marked influence on IUC
uptake rates. This is particularly evident in countries with
Table 3
HCPs for IUC by country
Country Provider Location
Obstetrician/
Gynecologist
Family practice
physician or
general practitioner
Nurse,
midwife or
other provider
Provider's
office
Sexual health,
contraception
or youth clinic
Abortion
clinic
Hospital-based
community
clinic
Europe
Germany ✓ ✓
UK ✓ ✓ ✓ ✓ ✓
France ✓ ✓ ✓ ✓ ✓ ✓ ✓
The Netherlands ✓ ✓ ✓ ✓ ✓
Sweden ✓ ✓ ✓ ✓ ✓ ✓
North America
USA ✓ ✓ ✓ ✓ ✓ ✓ ✓
Canada ✓ ✓ ✓ ✓ ✓ ✓
Latin America
Mexico ✓ ✓ ✓ ✓ ✓ ✓
Costa Rica ✓ ✓ ✓ ✓ ✓
Colombia ✓ ✓ ✓ ✓ ✓ ✓ ✓
Argentina ✓ ✓ ✓ ✓ ✓
Brazil ✓ ✓ ✓ ✓ ✓
Asia/Asia-Pacific
China ✓ ✓ ✓ ✓
India ✓ ✓ ✓ ✓ ✓ ✓
Australia ✓ ✓ ✓ ✓ ✓ ✓
170 K.J. Buhling et al. / Contraception 89 (2014) 162–173geographically isolated rural populations who are unable to
travel to clinics offering IUC services. For example, in
Turkey, initial attempts to extend access to IUC in rural
areas via physician-run mobile clinics were less successful
than anticipated owing to difficulties in providing adequate
postplacement follow-up care [4]. Initial research under-
taken to assess whether IUC placements and removals
could be performed safely by local midwives who could
provide both immediate and follow-up care at a location
accessible to women living in rural villages [21]. The
study demonstrated that nurses were at least as careful as
physicians in performing IUC placements and, based on
these findings, the Turkish Government authorized mid-
wives to provide IUC services. A similar approach has
been studied in Sudan in the late 90s when midwives
undertook a 3-week training course for the insertion of
IUDs. The rate of incorrect insertions was evaluated in 520
patients, and just 6 (1.2%) IUDs were found to have been
incorrectly placed [22]. This contributed to a steady and
sustained increase in IUC use over the following decade
[4]. In contrast, one study has shown a higher failure rate
when IUC was inserted by nurses compared to physicians.
This fact was discussed as the result of an insufficient
training in nurses [23].
The provision of IUC services in Egypt used to be the sole
prerogative of obstetrician-gynecologists. However, since
the mid-1980s, a steady increase in IUC use has been
achieved, in part by allowing general practitioners to place
and remove devices, with careful attention given to the
training and certification of these providers [4]. In addition,
since the mid-1990s, nurses have been trained and provided
with incentives to place IUC [24].3.3.2. Availability of practical training
An important factor-limiting access to IUC is the
availability of providers who have the skills, time and
support to train other HCPs. In the UK, a shortage of trainers
has led to waiting lists for training program opportunities and
hence a delay in physicians gaining the Letter of Compe-
tence in Intrauterine Techniques qualification [25].
3.4. Locations at which IUC services are accessed
The locations at whichwomen can access IUC services also
vary between countries (Table 3). For example, in Germany,
IUC services are provided only in obstetrician-gynecologists'
offices. However, in many other countries, IUC services can
be accessed at a choice of locations, including HCPs' offices,
sexual health clinics, contraception or youth clinics, abortion
clinics and hospital-based community clinics.
3.5. The medicolegal environment
The medicolegal environment can impact IUC provi-
sion, and fear of liability has frequently been cited by US-
based physicians as a barrier to more liberal prescribing of
these methods [26–28]. This may include fear of liability
for uterine perforation and, in particular, the fear that if the
woman at any point experiences pelvic inflammatory
disease or infertility, she may blame it on the LNG-IUS/
copper IUD and the provider who placed it. In a survey of
Fellows of the American College of Obstetricians and
Gynecologists (ACOG) conducted in 2002, a significant
correlation (p b .001) was found between physicians' fear
of litigation and a lower number of IUC placements
performed the previous year [29]. However, outside the
171K.J. Buhling et al. / Contraception 89 (2014) 162–173US, fear of litigation is much less of a barrier to HCPs
offering IUC services.
3.6. Factors at the HCP level
HCPs' attitudes have a strong influence on rates of IUC
use. The likelihood that an HCP will prescribe IUC depends
on many factors, including the providers' knowledge base,
and whether they have received appropriate training on
placement/removal techniques and patient counseling [30].
Several misperceptions remain among HCPs regarding the
efficacy and safety of IUC and the types of women for whom
it is unsuitable [30–34].
The degree to which these misperceptions curtail IUC use
in individual countries may depend on the persistence of
these misperceptions and the success that educational
programs have had in dispelling them. Family planning
experts in the US for example are actively addressing the
misperceptions among women and HCPs regarding the
safety of IUC and the unsuitability of these methods for
certain groups of women (e.g., nulliparous women and
adolescents) [30,35].
3.7. Factors at the end-user level: religious and
cultural influences
Cultural and religious influences in different countries
create environments that are more or less favorable to IUC
use. For example, in Muslim countries, bleeding distur-
bances associated with IUC interfere with women's religious
and social activities [36]. In contrast, in Mexico, IUC is
widely used, in part because Mexican women appreciate the
confidentiality that this type of contraception offers [4].
3.8. Variation in local guidelines and package inserts
International guidelines, in the form of the World Health
Organization (WHO) Medical Eligibility Criteria (MEC)
[37], exist to guide contraceptive practice throughout the
world. Individual countries also produce their own guide-
lines such as US Center for Disease Control and Prevention
MEC [38], the UKMEC [39] and Australian guidelines [40],
which are broadly based on the WHO recommendations. All
of these have relaxed recommendations regarding IUC use in
nulliparous women and adolescents and after first- or
second-trimester abortions. However, some national guide-
lines have been slow to acknowledge the evidence support-
ing use of IUC in nulliparous women; for example, the
German guidelines continue to regard IUC as a second
choice for nulliparous women [41], whereas no such
restrictions are mentioned in the Australian product
information [42].
There are also variations between countries in the package
inserts for different intrauterine contraceptives. For example,
in the US, although the package insert for the copper IUD
(ParaGard®) was revised significantly in 2005 (the restric-
tive “recommended patient profile” was removed entirely),
the current package insert for the LNG-IUS (Mirena®) doesnot support use in nulliparous women; the insert recom-
mends use in “women who have had at least one child” [43].
There are between-country divergences in preplacement
screening practices that are not always evidence based but
are driven by local recommendations. One example of such a
divergence is the use of preplacement screening for sexually
transmitted infections (STIs). In the US, the ACOG
guidelines state that for a woman at high risk of STIs (e.g.,
aged ≤25 years or with multiple sexual partners), it is
reasonable to screen for STIs and then place the IUC on the
same day (and subsequently treat the infection if the results
are positive) or alternatively wait until the test results are
available before placing IUC [44]. In the UK, National
Institute for Health and Clinical Excellence guidance
recommends that women “at risk of STIs” should be tested
for chlamydia and gonorrhea (if the woman lives in an area
where gonorrhea is prevalent) before placement of IUC and,
if STI screening is not possible, antibiotic prophylaxis
should be given before IUC placement [2].
Guidelines regarding cervical cancer screening require-
ments before IUC placement also vary between countries.
For example, in Germany, a Pap smear within 6 months of
placement is mandatory [41], whereas in the UK, preplace-
ment Pap smears are not mandated [2]. Taking the Pap smear
before IUD placement is not really based on evidence-based
facts [44]. These examples should give an impression how
national guidelines as well as country-specific labeling are
likely to contribute to diversity of practice.
3.9. Limitations
Unfortunately, we could not explore all barriers and
country-specific reasons, as there are very complicated and
sometimes not well-documented factors related to political,
religious or other beliefs.4. Conclusions
There is considerable variation between continents and
countries in the rates of IUC use and the types of device that
are used. Multiple factors contribute to this variability,
including government policy, funding for contraception,
types of HCP involved in IUC placement and types of clinics
that provide IUC services. In addition, the geographic
distribution of clinics providing IUC services (e.g., lack of
access in rural areas), differences in how IUC services are
funded and misperceptions regarding the unsuitability of
IUC for certain groups of women appear to have a substantial
impact on IUC use. The religious and sociocultural
sensitivities in different countries also create environments
that are more or less favorable to IUC use.
Our review shows that in practice the use of IUC is
influenced more by factors including geographic differences,
government policy and the HCP's educational level than by
medical eligibility criteria. In order to increase the use of IUC
methods, which are both highly effective and highly cost-
172 K.J. Buhling et al. / Contraception 89 (2014) 162–173effective, a program of HCP education and health policy
changes will need to occur in those countries where low rates
of IUC uptake are documented. The US and the UK have
already recognized a need to increase IUC use and have
developed national evidence-based guidelines [2,44]. An
upward trend in IUC use has been documented in these
countries in the past few years [45,46]. Globally, a
compelling reason for governments and health care systems
to reduce the diversity in access to IUC is to make them
aware that IUC is among the most cost-effective methods
available [12,47].
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